Skip to main content
    Q

    Quoin Pharmaceuticals Ltd DRC (QNRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.70
    -0.05 (-1.33%)

    Market Cap: $17.78M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Quoin Pharmaceuticals Ltd DRC (QNRX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Quoin Pharmaceuticals Ltd DRC reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$15.80M, operating cash flow was -$13.54M and free cash flow was -$13.54M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$4.87M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $16.29M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018-$280.00KN/AN/AN/AN/A
    Dec 2017N/AN/AN/AN/AN/A
    Dec 2016-$280.00KN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$0$0$0$0-$280.00KN/A-$280.00K
    Cost of revenue$100.79K$100.47K$103.44K$103.64K$104.11K$104.77K$227.06K$125.72K$104.22K$89.13K
    Gross profit-$100.79K-$100.47K-$103.44K-$103.64K-$104.11K-$104.77K-$227.06K-$280.00K-$104.22K-$280.00K
    Research and development$9.80M$3.60M$3.31M$2.67M$1.56M$244.16K$45.65K$8.26M$5.89M$8.26M
    Operating income-$16.29M-$9.53M-$9.38M-$9.26M-$6.06M-$1.67M-$1.56M$15.32M$10.17M$15.32M
    Net income-$15.80M-$8.96M-$8.69M-$9.38M-$21.46M-$2.10M-$1.56M$15.32M$10.17M$15.32M
    EBITDA-$15.70M-$8.86M-$8.58M-$8.56MN/A-$1.57M-$1.54M$15.32M$10.17M$15.32M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$100.37K$0$0$0$154.77K
    Gross profitN/A-$25.43K-$24.93K-$25.16KN/A-$25.52K-$24.87K$50.19K-$25.07K-$24.91K-$25.28K-$25.95K
    Operating income-$4.92M-$5.57M-$5.13M-$4.52M-$4.02M-$3.79M-$3.96M-$2.41M-$2.53M-$2.14M-$2.46M-$2.22M
    Net income-$4.87M-$5.46M-$5.00M-$4.35M-$3.95M-$3.70M-$3.81M-$2.31M-$2.35M-$1.97M-$2.33M-$2.05M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $3.82B were 18734.7% of total assets of $20.39M, against total liabilities of $7.27M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$20.39M$15.71M$12.17M$14.46M$9.36M$1.38M$6.17M$5.52M$8.75M$8.81M
    Current assets$20.01M$14.93M$11.29M$13.37M$8.20M$465.17K$5.38M$4.98M$8.22M$8.42M
    Cash and equivalents$3.82B$3.62M$2.40M$2.86M$7.48M$323.83K$5.24M$4.77M$3.96M$1.63M
    Total liabilities$7.27M$6.50M$6.51M$7.05M$8.70M$7.99M$1.88M$1.80M$3.32M$1.41M
    Short-term debtN/AN/AN/AN/AN/A$1.21M$114.65KN/AN/A$15.07K
    Shareholder equity$13.12M$9.20M$5.66M$7.41M$657.03K-$6.61M$4.30M$3.73M$5.43M$7.40M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$34.75M$11.97M$15.69M$20.39M$6.42M$8.91M$12.96M$15.71M$11.39M$14.05M$16.12M$12.17M
    Total liabilities$6.05M$8.04M$6.92M$7.27M$7.64M$6.36M$7.03M$6.50M$5.95M$6.58M$7.00M$6.51M
    Cash and equivalents$10.10M$3.85M$3.12M$3.82B$1.83M$1.67M$3.82M$3.62M$3.12M$2.85M$1.83M$2.40M
    Shareholder equity$28.70M$3.93M$8.77M$13.12M-$1.21M$2.55M$5.93M$9.20M$5.44M$7.48M$9.13M$5.66M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$13.54M-$7.86M-$7.86M-$8.48M-$5.72M-$1.34M-$5.71M-$6.57M-$4.98M-$3.77M
    Capital expenditures$4$0N/A$250.00K$625.00K$125.00K$34.52K$182.46K$74.53K$330.64K
    Free cash flow-$13.54M-$7.86MN/A-$8.73M-$6.35M-$1.46M-$5.74M-$6.76M-$5.05M-$4.10M
    Dividends paidN/AN/AN/A$65.27MN/AN/AN/AN/AN/AN/A
    Investing cash flow-$4.28M-$1.89M$2.19M-$10.15M-$625.00K-$125.00K-$30.31K$3.81M$2.83M-$4.71M
    Financing cash flow$18.01M$10.97M$5.22M$14.01M$13.50M$1.79M$6.14M$3.55M$4.43M$9.13M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$5.77M-$3.21M-$4.87M-$5.08M-$2.23M-$3.69M-$2.59M-$2.24M-$2.18M-$2.01M-$1.43M-$3.22M
    Capital expenditures$0$3$0$4$0N/A$0$0N/AN/AN/A$0
    Free cash flow-$5.77M-$3.21M-$4.87M-$5.08M-$2.23MN/A-$2.59M-$2.24MN/AN/AN/A-$3.22M
    Last 12 quarters

    Frequently Asked Questions About QNRX

    What is Quoin Pharmaceuticals Ltd DRC's annual revenue?

    Quoin Pharmaceuticals Ltd DRC reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Quoin Pharmaceuticals Ltd DRC profitable?

    No. Quoin Pharmaceuticals Ltd DRC reported net income of -$15.80M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does QNRX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$13.54M minus capital expenditures of $4 produced free cash flow of -$13.54M.

    How much debt does Quoin Pharmaceuticals Ltd DRC have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $3.82B.